Eric Brown, MD
Nephrology · Albuquerque, NMNPI 1508962093
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AstraZeneca at 42.5% of the total. That places this record below the midpoint for nephrology clinicians in NM, where the typical reported total is $1,114.
Across 25 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$192
- Bayer$85
- Otsuka America Pharmaceutical, Inc.$63
- Aurinia Pharma U.S., Inc.$38
- Fresenius USA Marketing, Inc.$23
- Amgen$21
- plus $31 from 2 others
Across 94 payments — averaging $1116.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$105K
What the payments were for
- Food & beverage$453100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 11 | $192 |
| Bayer | 5 | $85 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| Aurinia Pharma U.S., Inc. | 2 | $38 |
| Fresenius USA Marketing, Inc. | 1 | $23 |
| Amgen | 1 | $21 |
| Travere Therapeutics, Inc. | 1 | $20 |
| Merck | 1 | $12 |
How this compares
$453 in reported general payments places this provider in the 30th percentile of 68 nephrology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 22 | $37,973 |
| Chlorthalidone | 29 | $691 |
| Losartan Potassium | 33 | $571 |
| Amlodipine Besylate | 30 | $241 |
| Lisinopril | 29 | $241 |
| Olmesartan Medoxomil | 15 | $219 |
| Carvedilol | 20 | $135 |
| Irbesartan | 14 | $114 |
| Spironolactone | 17 | $95 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Albuquerque
- Satyaki BanerjeeAlbuquerque$260K
- Christos ArgyropoulosAlbuquerque$32K
- Arun RajasekaranAlbuquerque$32K
- George Vasquez RiosAlbuquerque$25K
- Jayant KumarAlbuquerque$12K
- Luis Madera MarinAlbuquerque$7K
- Hector CastroAlbuquerque$7K
- Chudi AdiAlbuquerque$7K
- Dale EricksonAlbuquerque$6K
- Lei ChenAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.